Patents by Inventor Brendan M. Crowley

Brendan M. Crowley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240368109
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ? 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Application
    Filed: September 19, 2022
    Publication date: November 7, 2024
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Ian M. Bell, Brendan M. Crowley, James Fells, Patrick Bazzini, Jean-Marie Contreras, Fabrice Garrido, Belinda C. Huff, Christophe Joseph, Christophe Morice, Dharam Paul, Aurelie Witzel
  • Publication number: 20240208958
    Abstract: The present invention relates to the oxazolidinone compound of Formula (I): and pharmaceutically acceptable salts thereof. The present invention also relates to compositions containing the compound of Formula (I). The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering a therapeutically effective amount of Formula (I) and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.
    Type: Application
    Filed: March 20, 2021
    Publication date: June 27, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Brendan M. CROWLEY, Philippe NANTERMET, David B. OLSEN, Takao SUZUKI, Lihu YANG, Lanying YOU
  • Publication number: 20240083910
    Abstract: The present invention relates to novel Amido-Substituted Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 14, 2021
    Publication date: March 14, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Richard Thaddeus Berger, JR., Christopher Douglas Cox, Brendan M. Crowley, Marc Labroli, Michael Aaron Plotkin, Izzat Tiedje Raheem, Deyou Sha, Anthony W. Shaw, Jason W. Skudlarek, Ling Tong
  • Publication number: 20240067657
    Abstract: The present invention relates to novel Amido-Substituted Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R7, and R8 are as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Heterocycle Compound, and methods of using the Amido-Substituted Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 21, 2021
    Publication date: February 29, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Kira A. Armacost, Richard Thaddeus Berger, Jr., Andrew J. Cooke, Christopher Douglas Cox, Brendan M. Crowley, Marc Labroli, Michael Aaron Plotkin, Izzat Tiedje Raheem, Anthony W. Shaw, Kelly-Ann S. Schlegel, Jason W. Skudlarek, Ling Tong
  • Publication number: 20240018145
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing influenza. The compounds are cap-dependent endonuclease inhibitors.
    Type: Application
    Filed: July 22, 2021
    Publication date: January 18, 2024
    Applicants: Merck Sharp & Dohme LLC, COCRYSTAL PHARMA, INC.
    Inventors: Yonglian Zhang, John A. McCauley, Michael Man-Chu Lo, Liangqin Guo, Kake Zhao, Frank Bennett, Ronald M. Kim, Reynalda Keh DeJesus, Valerie W. Shurtleff, Manuel de Lera Ruiz, Michael Plotkin, Hua Su, James Fells, Brendan M. Crowley, Harry R. Chobanian, Mark W. Embrey, Gregori J. Morriello
  • Patent number: 11793821
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: October 24, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Brendan M. Crowley, Ian M. Bell, Andrew John Harvey
  • Publication number: 20230054782
    Abstract: The present invention relates to novel Bicyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, Z, R1 R5, R6, and R7 are as defined herein. The present invention also relates to compositions comprising at least one Bicyclic Heterocycle Compound, and methods of using the Bicyclic Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 17, 2020
    Publication date: February 23, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Andrew John Cooke, Brendan M. Crowley, Marc A. Labroli, Michael Aaron Plotkin, Izzat T. Raheem, Ling Tong, Deyou Sha
  • Publication number: 20220396571
    Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Application
    Filed: October 29, 2020
    Publication date: December 15, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ian M. Bell, Brendan M. Crowley, Phillippe Nantermet
  • Publication number: 20220235041
    Abstract: Disclosed are dihydroisoxazole compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. Also disclosed are compositions which comprise at least one of these dihydroisoxazole compounds, methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of these dihydroisoxazole compounds and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.
    Type: Application
    Filed: June 2, 2020
    Publication date: July 28, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Brendan M. Crowley, Philippe Nantermet, David Olsen, Takao Suzuki
  • Patent number: 11332463
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I).
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: May 17, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Brendan M. Crowley, Brian T. Campbell, Harry R. Chobanian, James I. Fells, Deodial G. Guiadeen, Thomas J. Greshock, Kenneth J. Leavitt, Vanessa L. Rada, Ian M. Bell
  • Publication number: 20220119351
    Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of 7? nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Application
    Filed: April 27, 2020
    Publication date: April 21, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ian M. Bell, Brian T. Campbell, Brendan M. Crowley, James Fells, Kenneth J. Leavitt, Anthony J. Roecker, Andrew John Harvey, Belinda C. Huff, Dharam Paul, Christophe Morice, Christophe Joseph, Patrick Bazzini, Jean-Marie Contreras, Fabrice Garrido, Aurelie Witzel
  • Patent number: 11198687
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I).
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: December 14, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ian M. Bell, Brendan M. Crowley, Peter J. Manley, William D. Shipe
  • Publication number: 20210196734
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation
    Type: Application
    Filed: March 5, 2021
    Publication date: July 1, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Brendan M. Crowley, Ian M. Bell, Andrew John Harvey, Brian T. Campbell, Thomas J. Greshock, Vanessa L. Rada
  • Patent number: 11026958
    Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: June 8, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Brendan M. Crowley, Ian M. Bell, Andrew John Harvey, Brian T. Campbell, Thomas J. Greshock, Vanessa L. Rada
  • Publication number: 20210077511
    Abstract: present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Application
    Filed: October 30, 2017
    Publication date: March 18, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: BRENDAN M. CROWLEY, IAN M. BELL, ANDREW JOHN HARVEY, BRIAN T. CAMPBELL, THOMAS J. GRESHOCK, VANESSA L. RADA
  • Publication number: 20210070745
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I).
    Type: Application
    Filed: April 29, 2019
    Publication date: March 11, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Brendan M. Crowley, Brian T. Campbell, Harry R. Chobanian, James I. Fells, Deodial G. Guiadeen, Thomas J. Greshock, Kenneth J. Leavitt, Vanessa L. Rada, Ian M. Bell
  • Patent number: 10870630
    Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: December 22, 2020
    Inventors: Brendan M. Crowley, Ian M. Bell, Andrew John Harvey, William D. Shipe, Kenneth J. Leavitt, John M. Sanders, Deodial G. Guiadeen, Linda M. Suen, Thomas J. Greshock, Vanessa L. Rada
  • Publication number: 20200262826
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I).
    Type: Application
    Filed: September 14, 2018
    Publication date: August 20, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ian M. Bell, Brendan M. Crowley, Peter J. Manley, William D. Shipe
  • Publication number: 20190337910
    Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Application
    Filed: March 20, 2017
    Publication date: November 7, 2019
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: BRENDAN M. CROWLEY, BRIAN T. CAMPBELL, JOSEPH L. DUFFY, THOMAS J. GRESHOCK, DEODIAL G. GUIADEEN, ANDREW JOHN HARVEY, BELINDA C. HUFF, KENNETH J. LEAVITT, VANESSA L. RADA, JOHN M. SANDERS, WILLIAM D. SHIPE, LINDA M. SUEN, IAN M. BELL
  • Publication number: 20190308945
    Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Application
    Filed: October 30, 2017
    Publication date: October 10, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: BRENDAN M. CROWLEY, IAN M. BELL, ANDREW JOHN HARVEY, WILLIAM D. SHIPE, KENNETH J. LEAVITT, JOHN M. SANDERS, DEODIAL GUY GUIADEEN, LINDA M. SUEN, THOMAS J. GRESHOCK, VANESSA L. RADA